1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Brain Neoplasms in 7 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 7.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| "Resistance to temozolomide (TMZ) is a major clinical challenge in glioma treatment, but the mechanisms of TMZ resistance are poorly understood." | 3.88 | Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. ( Ding, Y; Hu, R; Liu, X; Wang, Q; Yang, M; Zhang, X; Zhou, W, 2018) |
| "Malignant gliomas are characterized by high invasive potential and strong angiogenic ability." | 1.37 | HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways. ( Nakabayashi, H; Shimizu, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Liu, X | 1 |
| Zhou, W | 1 |
| Yang, M | 1 |
| Ding, Y | 1 |
| Wang, Q | 1 |
| Hu, R | 1 |
| He, M | 1 |
| Luo, M | 1 |
| Liu, Q | 1 |
| Chen, J | 1 |
| Li, K | 1 |
| Zheng, M | 1 |
| Weng, Y | 1 |
| Ouyang, L | 1 |
| Liu, A | 1 |
| Shenkar, R | 1 |
| Shi, C | 1 |
| Austin, C | 1 |
| Moore, T | 1 |
| Lightle, R | 1 |
| Cao, Y | 1 |
| Zhang, L | 1 |
| Wu, M | 1 |
| Zeineddine, HA | 1 |
| Girard, R | 1 |
| McDonald, DA | 1 |
| Rorrer, A | 1 |
| Gallione, C | 1 |
| Pytel, P | 1 |
| Liao, JK | 1 |
| Marchuk, DA | 1 |
| Awad, IA | 1 |
| Nakabayashi, H | 1 |
| Shimizu, K | 1 |
| Kugaya, A | 1 |
| Kagaya, A | 1 |
| Uchitomi, Y | 1 |
| Motohashi, N | 1 |
| Yamawaki, S | 1 |
| Van Wagoner, NJ | 1 |
| O'Keefe, GM | 1 |
| Benveniste, EN | 1 |
| Miñana, MD | 1 |
| Felipo, V | 1 |
| Cortés, F | 1 |
| Grisolía, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Brain Neoplasms
| Article | Year |
|---|---|
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Combination treatment with fasudil and clioquinol produces synergistic anti-tumor effects in U87 glioblastoma cells by activating apoptosis and autophagy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Autophagy; Blotting, Western; Bra | 2016 |
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Disease Models, Animal; Fem | 2017 |
HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Blotting, Western; Brain Neopl | 2011 |
Inhibition of serotonin-induced Ca2+ mobilization by interleukin-1 beta in rat C6BU-1 glioma cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Calcium; Cell Division; Enz | 1995 |
Kinase inhibitors abrogate IFN-gamma-induced class II transactivator and class II MHC gene expression in astroglioma cell lines.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Astrocytoma; Brain Neoplasms; Enzyme Inhibitors; Gene | 1998 |
Inhibition of protein kinase C arrests proliferation of human tumors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Ce | 1991 |